Insmed (NASDAQ:INSM) Earns “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Insmed (NASDAQ:INSM) in a report released on Monday, Benzinga reports.

A number of other research firms have also recently commented on INSM. Truist Financial dropped their target price on shares of Insmed from $88.00 to $85.00 and set a buy rating for the company in a report on Monday, August 12th. Wells Fargo & Company increased their target price on shares of Insmed from $55.00 to $77.00 and gave the stock an overweight rating in a report on Wednesday, May 29th. JPMorgan Chase & Co. increased their target price on shares of Insmed from $55.00 to $72.00 and gave the stock an overweight rating in a report on Thursday, June 20th. Mizuho increased their target price on shares of Insmed from $36.00 to $82.00 and gave the stock a buy rating in a report on Friday, June 7th. Finally, Evercore ISI increased their target price on shares of Insmed from $42.00 to $75.00 and gave the stock an outperform rating in a report on Friday, June 21st. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, Insmed currently has a consensus rating of Moderate Buy and a consensus target price of $79.19.

Insmed Trading Up 1.7 %

INSM opened at $72.76 on Monday. Insmed has a twelve month low of $21.92 and a twelve month high of $80.53. The company has a 50-day simple moving average of $74.11 and a 200 day simple moving average of $49.65. The company has a quick ratio of 2.53, a current ratio of 2.71 and a debt-to-equity ratio of 25.05. The stock has a market capitalization of $10.81 billion, a price-to-earnings ratio of -14.00 and a beta of 1.11.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The company had revenue of $90.34 million for the quarter, compared to analyst estimates of $87.95 million. During the same period last year, the company earned ($1.78) earnings per share. The firm’s revenue for the quarter was up 17.0% compared to the same quarter last year. Analysts predict that Insmed will post -5.42 EPS for the current fiscal year.

Insider Buying and Selling at Insmed

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the completion of the sale, the insider now owns 100,100 shares of the company’s stock, valued at approximately $7,157,150. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.60% of the company’s stock.

Institutional Trading of Insmed

Large investors have recently modified their holdings of the stock. First Horizon Advisors Inc. grew its position in shares of Insmed by 83.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 287 shares during the period. EntryPoint Capital LLC acquired a new stake in shares of Insmed during the 1st quarter worth approximately $33,000. Fidelis Capital Partners LLC acquired a new stake in shares of Insmed during the 1st quarter worth approximately $34,000. CWM LLC grew its position in shares of Insmed by 11.0% during the 2nd quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 155 shares during the period. Finally, Nisa Investment Advisors LLC grew its position in shares of Insmed by 8.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 135 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.